Codon Capital
VC Fund
San Francisco, United States
Codon Capital is a venture capital firm that brings entrepreneurs and researchers to discover strategies for translating innovation into products and startup companies. It focuses on two biology disciplines, Therapeutics and Synthetic Biology, each with unique investment benefits. Together, they represent the new biology design revolution,opportunities that will define healthcare, and agriculture.Founded in 2013 by Karl Handelsman, Codon Capital is headquartered in San Francisco, California.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Codon Capital invests in
Stages Codon Capital invests in
Countries Codon Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Karl Handelsman
|
|||
Investment Focus
Industry
- Biotechnology 7 (88%)
- Medical 4 (50%)
- Life Science 4 (50%)
- Health Care 3 (38%)
- Therapeutics 3 (38%)
Stage
- Series A 5 (63%)
- Series B 2 (25%)
- Series C 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Karl Handelsman
Founder and Investor
|
Founder and Investor | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EpiBiologics
|
EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M / Series B / Jan 08, 2026 | |
Seismic Therapeutic
|
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements ofbiologics drug discovery – structural biology, protein engineering, and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. | $121M / Series B / Dec 04, 2023 | |
AIRNA
|
AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments. | $30M / Series A / Sep 19, 2023 | |
|
EpiBiologics
|
EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $23M / Series A / Jul 20, 2023 | |
Bonum Therapeutics
|
Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management. | $93M / Series A / Nov 15, 2022 | |
Ansa Biotechnologies
|
Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerateinnovation in biological research and engineering. | $68M / Series A / Apr 11, 2022 | |
Good Therapeutics
|
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer,more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology. | $11M / Series A / May 21, 2020 | |
Pivot Bio
|
Pivot Bio is improving and using a deep understanding of the microbiome to advance crop nutrition. They believe that microbes can deliver nutrients, protect against pests, and improve crop quality better than chemical fertilizers and pesticides. They leverage engineering principles and data science to map the dynamics of the plant microbiome andevolve beneficial traits. Their team thrives on collaboration and communication as they seek to create revolutionary fertilizers that transform food supply and improves the planet.Pivot Bio's proprietary ON Technology harnesses the power of naturally occurring microbes to provide more nutrients to crops. It’s a smart, sustainable way for farmers to improve yield as they work to help feed the world’s growing population. Their current efforts are focused on enabling microbes to fix and supply more nitrogen to corn.Pivot Bio was founded in 2010 and is headquartered in Berkeley, California, United States. | $100M / Series C / Apr 30, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Codon Capital invest in?
Codon Capital invests primarily in Biotechnology, Medical and Life Science startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Codon Capital?
Public channels for Codon Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Codon Capital?
The team at Codon Capital includes Karl Handelsman (Founder and Investor). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
